Ranbaxy receives FDA approval for generic migraine treatment

PRINCETON, N.J. A generic drug maker has received approval from the Food and Drug Administration to manufacture and market a popular migraine medication.

Ranbaxy Pharmaceuticals has received final approval from the FDA to manufacture and market sumatriptan succinate tablets in 25- and 50-mg strengths. The medication is the generic equivalent of Imitrex, a migraine treatment by GlaxoSmithKline. Total annual market sales for the tablets were $379 million, which is indicated for the acute treatment of migraine attacks with or without aura in adults.

“This product will be launched immediately to all classes of trade and further expands our product portfolio of affordable generic product formulations, that will be of benefit to patients, healthcare professionals and the U.S. healthcare system,” according to Bill Winter, VP trade sales North America at Ranbaxy.